600812 华北制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)2.9102.3730.092-12.1070.307
总资产报酬率 ROA (%)0.7370.5990.023-2.9870.077
投入资产回报率 ROIC (%)0.9100.7260.028-3.5930.091

边际利润分析
销售毛利率 (%)29.25131.96631.98133.38035.456
营业利润率 (%)3.8333.1581.546-5.4061.310
息税前利润/营业总收入 (%)7.3407.4536.238-0.1296.850
净利润/营业总收入 (%)2.8262.1780.488-6.4650.341

收益指标分析
经营活动净收益/利润总额(%)78.96986.30948.541-33.27119.751
价值变动净收益/利润总额(%)14.65914.90029.552-7.79028.996
营业外收支净额/利润总额(%)0.108-0.5971.314-0.453-0.835

偿债能力分析
流动比率 (X)0.6720.7530.7810.7240.893
速动比率 (X)0.4900.5240.5270.5210.725
资产负债率 (%)69.01268.91470.07970.65071.852
带息债务/全部投入资本 (%)66.48267.26067.43867.07069.084
股东权益/带息债务 (%)48.04045.49845.40745.22242.174
股东权益/负债合计 (%)37.03936.42336.19235.35233.973
利息保障倍数 (X)2.0951.7281.335-0.0241.234

营运能力分析
应收账款周转天数 (天)80.65872.59274.02671.82664.012
存货周转天数 (天)121.446137.207134.173126.481130.109